Overview Quality Outlook Risk & rank Results Accounts Options Guidance & governance
Guidance tracker
What CIPLA guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 30 Oct 2026 | Cipla filed the transcript of its Q2 FY27 earnings conference call held on 27 October 2026. Management reported Q2 FY27 revenue of INR 7,404 crores, up 4% quarter-on-quarter, with EBITDA margin excluding other income at 18.7% (up 200 basis points sequentially) and profit after tax of INR 878 crores (11.9% of... NSE copy | No results filed since | ||
| 27 Jul 2026 | Cipla filed the transcript of its Q1 FY27 earnings conference call held on 23 July 2026. Management (Achin Gupta, MD and Global CEO) said Q1 revenue of INR 7,100 crores was the highest ever first quarter; One India revenue grew 12% Y-o-Y and North America revenue was 162 million. CFO Ashish Adukia reported... NSE copy | -35.1 % | -2.4 % | -0.4 % |
| 15 May 2026 | Cipla filed the transcript of its Q4 FY26 earnings conference call held on 13 May 2026. Management reported Q4 FY26 revenue of INR 6,541 crores and FY26 revenue of INR 28,163 crores; EBITDA margin 15.2% for the quarter and 21% for the year (excluding other income); PAT INR 555 crores for the quarter and INR 3,879... NSE copy | -39.2 % | +2.3 % | -1.6 % |
| 27 Jan 2026 | Cipla filed the transcript of its Q3 FY26 earnings conference call held on 23 January 2026. Ashish Adukia (Global CFO) said quarterly revenue was Rs 7,074 crores, flat YoY, with EBITDA margin excluding other income at 17.7%, hit by lower generic Revlimid revenues. Management said FY26 EBITDA margin guidance is... NSE copy | -54.6 % | -2.8 % | +2.7 % |
| 03 Nov 2025 | Cipla filed the transcript of its Q2 FY26 earnings conference call held on 30 October 2025. Management reported an all-time high quarterly revenue of INR7,589 crores, up 8% year-on-year, with an EBITDA margin of 25% excluding other income and profit after tax of INR1,351 crores (17.8% of sales). Management revised... NSE copy | -57.0 % | +0.0 % | -4.0 % |
| 28 Jul 2025 | Cipla filed the transcript of its Q1 FY26 earnings conference call held on 25 July 2025. Management reported quarterly revenue of INR 6,957 crores (up 4% Y-o-Y), EBITDA margin excluding other income of 25.6%, and profit after tax of INR 1,298 crores (18.7% of sales, up 10.2% Y-o-Y). Management maintained full-year... NSE copy | +3.7 % | +7.6 % | -2.6 % |
| 16 May 2025 | Cipla filed the transcript of its Q4 FY25 earnings conference call held on 13 May 2025. Management reported Q4 revenue of INR 6,730 crores (up 9% Y-o-Y) and FY25 revenue of INR 27,548 crores (up 8%); Q4 EBITDA margin 22.8% and FY25 EBITDA margin 25.9%, excluding other income. Q4 PAT was INR 1,222 crores (18.2% of... NSE copy | +10.2 % | +3.9 % | +3.0 % |
| 31 Jan 2025 | Cipla filed the transcript of its Q3 FY25 earnings conference call held on 28 January 2025. Management reported quarterly revenue of Rs 7,073 crore, up 8% YoY (adjusted for QCIL divestment), with EBITDA margin of 28% and profit after tax of Rs 1,571 crore (about 22% of sales). Management retained its FY26 guidance... NSE copy | +30.1 % | +9.2 % | +0.6 % |
| 02 Nov 2024 | Cipla filed the transcript of its Q2 FY25 earnings conference call held on 29 October 2024. Management reported quarterly revenue of Rs. 7,051 crore (up 9% YoY, adjusted for QCIL divestment), EBITDA margin excluding other income of 26.7%, and profit after tax of Rs. 1,303 crore. Management said the EBITDA margin... NSE copy | +48.7 % | +7.1 % | +0.2 % |
| 29 Jul 2024 | Cipla filed the transcript of its Q1 FY25 earnings conference call held on 26 July 2024. Management reported quarterly revenue of INR6,694 crores, up 7%, with EBITDA margin (excluding other income) of 25.6%, up 154 basis points, and profit after tax of INR1,178 crores (17.6% of sales). Management said North America... NSE copy | +15.2 % | +5.6 % | -1.7 % |
| 15 May 2024 | Cipla filed the transcript of its Q4 FY24 earnings conference call held on 10 May 2024. Management said FY24 was the highest-ever revenue and EBITDA; FY24 revenue was INR25,455 crores (up 14% YoY) and Q4 revenue was INR6,163 crores (up 10% YoY), with full-year EBITDA margin of 24.5% and Q4 margin of 21.4%.... NSE copy | +18.3 % | +5.8 % | +5.0 % |
| 29 Jan 2024 | Cipla filed the transcript of its Q3 FY24 earnings conference call held on 25 January 2024. Management reported Q3 FY24 revenue of INR 6,544 crores, up 14%, with EBITDA margin of 26.3% (excluding other income) and profit after tax of INR 1,049 crores (16% of sales). North America revenue reached a record $230... NSE copy | +78.6 % | +7.4 % | -1.4 % |
| 31 Oct 2023 | Cipla filed the transcript of its Q2 FY24 earnings conference call held on 27 October 2023. Management reported record quarterly revenue of Rs.6,678 crores, up 15% year-on-year, with EBITDA of Rs.1,690 crores (26% margin) and profit after tax of Rs.1,131 crores. Management said the One India franchise grew 10% and... NSE copy | +31.8 % | +13.7 % | +7.0 % |
Filings tagged as guidance, newest first (13 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 30 Oct 2026 | Legal or regulatory | Cipla filed the transcript of its Q2 FY27 earnings conference call held on 27 October 2026. Management reported Q2 FY27 revenue of INR 7,404 crores, up 4% quarter-on-quarter, with EBITDA margin excluding other income at 18.7% (up 200 basis points sequentially) and profit after tax of INR 878 crores (11.9% of... NSE copy |
| 27 Oct 2026 | Management change | Cipla Limited's board, at its meeting held on 27 October 2026, approved the appointment of Ms Rashmi Joshi (DIN: 06641898) as an additional and independent director. The appointment is for 5 years, effective 27 October 2026 to 26 October 2031 (both days inclusive), subject to shareholder approval. Ms Joshi is a... NSE copy |
| 19 Aug 2026 | Legal or regulatory | Cipla Ltd filed a Regulation 30 disclosure on 19 August 2026 about the Scheme of Amalgamation of its wholly-owned subsidiary Inzpera Healthsciences Limited (Transferor Company) into Cipla Limited (Transferee Company). The Hon'ble NCLT, Mumbai Bench, by order dated 18 August 2026 in CA(CAA)/114/MB/2026, allowed the... NSE copy |
| 27 Jul 2026 | Management change | Cipla filed the transcript of its Q1 FY27 earnings conference call held on 23 July 2026. Management (Achin Gupta, MD and Global CEO) said Q1 revenue of INR 7,100 crores was the highest ever first quarter; One India revenue grew 12% Y-o-Y and North America revenue was 162 million. CFO Ashish Adukia reported... NSE copy |
| 23 Jul 2026 | Management change | Cipla Ltd filed a Regulation 30 disclosure dated 23 July 2026 on outcomes of its board meeting held the same day. Mr. Ashish Adukia relinquished the role of Global Chief Financial Officer and Key Managerial Personnel with effect from close of business hours on 23 July 2026, moving to an internal business leadership... NSE copy |
| 23 Jul 2026 | Legal or regulatory | Cipla Ltd filed unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, approved by the Board on 23 July 2026, with a limited review report from statutory auditor BSR & Co. LLP (unmodified conclusion). Consolidated total income for the quarter was ₹7,330.18 crores against... NSE copy |
| 04 Jul 2026 | Management change | Cipla filed a corrigendum dated 4 July 2026 correcting typographical errors in the transcript of its 90th Annual General Meeting, held on 25 June 2026 via video conferencing, which was earlier notified on 3 July 2026; the corrected transcript was enclosed. Chairman Dr Y K Hamied said the company completed 90 years... NSE copy |
| 03 Jul 2026 | Management change | Cipla filed the transcript of its 90th Annual General Meeting, held on 25 June 2026 by video conferencing. Managing Director and Global CEO Achin Gupta said FY2026 was the company's highest-ever annual revenue, of over ₹28,000 crores, with a 21% EBITDA margin and 13.8% profit after tax margin. Gupta said India... NSE copy |
| 15 May 2026 | Legal or regulatory | Cipla filed the transcript of its Q4 FY26 earnings conference call held on 13 May 2026. Management reported Q4 FY26 revenue of INR 6,541 crores and FY26 revenue of INR 28,163 crores; EBITDA margin 15.2% for the quarter and 21% for the year (excluding other income); PAT INR 555 crores for the quarter and INR 3,879... NSE copy |
| 13 May 2026 | Management change | Cipla Limited filed the outcome of its board meeting held on 13 May 2026, which concluded at 1:00 p.m. IST. The board approved convening the 90th Annual General Meeting on Thursday, 25 June 2026. The board approved grants under ESOS 2013-A and ESAR 2021: 25,323 stock options (1 year vesting), 1,51,066 stock options... NSE copy |
| 19 Mar 2026 | Management change | Cipla Limited filed the outcome of its Board meeting held on 19 March 2026, which ran from 1400 to 1715 hrs (IST). Mr P R Ramesh (DIN: 01915274), Lead Independent Director, was designated Vice-Chairman with effect from 1 April 2026. Mr Robert Stewart (DIN: 03515778) expressed his intention not to seek... NSE copy |
| 27 Jan 2026 | Legal or regulatory | Cipla filed the transcript of its Q3 FY26 earnings conference call held on 23 January 2026. Ashish Adukia (Global CFO) said quarterly revenue was Rs 7,074 crores, flat YoY, with EBITDA margin excluding other income at 17.7%, hit by lower generic Revlimid revenues. Management said FY26 EBITDA margin guidance is... NSE copy |
| 23 Jan 2026 | Management change | Cipla's Board at its meeting on 23 January 2026 approved the re-appointment of Mr P R Ramesh (DIN: 01915274) as Independent Director. The re-appointment is for a second term of five consecutive years, from 1 July 2026 to 30 June 2031 (both days inclusive), subject to shareholder approval. Mr P R Ramesh has been an... NSE copy |
| 03 Nov 2025 | Legal or regulatory, Management change | Cipla filed the transcript of its Q2 FY26 earnings conference call held on 30 October 2025. Management reported an all-time high quarterly revenue of INR7,589 crores, up 8% year-on-year, with an EBITDA margin of 25% excluding other income and profit after tax of INR1,351 crores (17.8% of sales). Management revised... NSE copy |
| 30 Oct 2025 | Management change | Cipla's board outcome dated 30 October 2025 reports that MD & Global CEO Umang Vohra does not intend to seek re-appointment upon completion of his term on 31 March 2026. Global Chief Operating Officer Achin Gupta is appointed Managing Director & Global CEO effective 1 April 2026 for five years up to 31 March 2031,... NSE copy |
| 30 Oct 2025 | Legal or regulatory | Cipla filed its Q2FY26 investor presentation dated 30 October 2025 under Regulation 30 of the SEBI Listing Regulations. Consolidated Q2FY26 revenue from operations was INR 7,589 Cr, up 7.6% YoY, described as the highest-ever quarterly revenue; EBITDA was INR 1,895 Cr (25.0% margin) and PAT was INR 1,351 Cr (17.8%... NSE copy |
| 30 Oct 2025 | Legal or regulatory | Cipla's board approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 on 30 October 2025; limited review report by Walker Chandiok & Co. LLP enclosed. Consolidated total revenue from operations for Q2 FY26 was ₹7,589.44 crore, against ₹7,051.02 crore in... NSE copy |
| 28 Jul 2025 | Legal or regulatory | Cipla filed the transcript of its Q1 FY26 earnings conference call held on 25 July 2025. Management reported quarterly revenue of INR 6,957 crores (up 4% Y-o-Y), EBITDA margin excluding other income of 25.6%, and profit after tax of INR 1,298 crores (18.7% of sales, up 10.2% Y-o-Y). Management maintained full-year... NSE copy |
| 25 Jul 2025 | Management change | Board of Cipla Ltd, at its meeting held on 25 July 2025, approved the grant of stock options and employee stock appreciation rights (ESARs). Stock options granted under ESOS 2013-A: 5,264, vesting 2 years from grant date, exercisable for 5 years from vesting date, exercise price INR 2 per option. ESARs granted... NSE copy |
| 25 Jul 2025 | Legal or regulatory | Cipla filed the outcome of its board meeting held on 25 July 2025, approving unaudited standalone and consolidated financial results for the quarter ended 30 June 2025. Consolidated revenue from operations for Q1 FY26 was Rs 6,957.47 crore, against Rs 6,693.94 crore in the year-ago quarter (unaudited). Consolidated... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (47 in all). A list of what was filed, not a judgement of the company.